VDAC1 and cancer: Ligands typically employed for targeting tumor cells include small molecules (e.g., proteins (such as asialoglycoprotein receptor), folic acid for cancer [111,112]), peptides (such as R-Tf-D-LP4, voltage-dependent anion channel 1 (VDAC1) based peptide), and nanoantibodies [113,114].